Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1108-1115

  Dinney, Colin P N ^a   Hansel, Donna ^b   McConkey, David ^a   Shipley, William ^c   Hagan, Michael ^d   Dreicer, Robert ^e   Lerner, Seth ^f   Czerniak, Bogdan ^a   Waldman, Fred ^g   Groshen, Susan ^h   True, Lawrence D ⁱ   Petricoin, Emanuel ^j   Theodorescu, Dan ^k   Hruszkewycz, Andrew ^l   Bajorin, Dean ^m  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j GEORGE MASON UNIVERSITY   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Bladder cancer; Neoadjuvant chemotherapy; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CHEMORADIOTHERAPY; CYSTECTOMY; GENE EXPRESSION PROFILING; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); NATIONAL HEALTH ORGANIZATION; PATHOLOGY; PROCEDURES; UNITED STATES; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOADJUVANT THERAPY; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84925963385     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.10.021     Document Type: Review

References (60)

1. Siegel R., Naishadham D., Jema A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Sjodahl G., Lauss M., Lovgren K., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012, 18:3377-3386.
3. Esserman L.J., Berry D.A., DeMichele A., et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30:3242-3249.
4. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
5. Mueller C., Edmiston K.H., Carpenter C., et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011, 6:e23780.
6. Rountree C.B., Van Kirk C.A., You H., et al. Clinical application for the preservation of phospho-proteins through in-situ tissue stabilization. Proteome Sci 2010, 8:6.
7. Hicks D.G., Boyce B.F. The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 2012, 87:14-17.
8. Sonpavde G., Sternberg C.N. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. BJU Int 2008, 102:1354-1360.
9. Bartz S.R., Zhang Z., Burchard J., et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006, 26:9377-9386.
10. Narod S.A. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010, 7:702-707.
11. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
12. Choudhury A., Nelson L.D., Teo M.T., et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010, 70:7017-7026.
13. Esserman L.J., Berry D.A., Cheang M.C., et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012, 132:1049-1062.
14. Troester M.A., Herschkowitz J.I., Oh D.S., et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276.
15. Choi W., Shah J.B., Tran M., et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 2012, 7:e30206.
16. Karni-Schmidt O., Castillo-Martin M., Shen T.H., et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011, 178:1350-1360.
17. Tran M.N., Choi W., Wszolek M.F., et al. The p63 isoform DNp63a inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of miR-205. J Biol Chem 2013, 288:3275-3288.
18. Brandt W.D., Matsui W., Rosenberg J.E., et al. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev 2009, 28:291-304.
19. Chan K.S., Espinosa I., Chao M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009, 106:14016-14021.
20. Ho P.L., Kurtova A., Chan K.S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 2012, 9:583-594.
21. Volkmer J.P., Sahoo D., Chin R.K., et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 2012, 109:2078-2083.
22. Bai Y., Tolles J., Cheng H., et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011, 91:1253-1261.
23. Espina V., Edmiston K.H., Heiby M., et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008, 7:1998-2018.
24. Espina V., Mueller C. Reduction of preanalytical variability in specimen procurement for molecular profiling. Methods Mol Biol 2012, 823:49-57.
25. Holzer T.R., Fulford A.D., Arkins A.M., et al. Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. Anticancer Res 2011, 31:2073-2081.
26. Silvestri A., Colombatti A., Calvert V.S., et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010, 90:787-796.
27. Wulfkuhle J.D., Speer R., Pierobon M., et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008, 7:1508-1517.
28. Dimou A., Agarwal S., Anagnostou V., et al. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 2011, 179:580-589.
29. Welsh A.W., Moeder C.B., Kumar S., et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011, 29:2978-2984.
30. Paweletz C.P., Charboneau L., Bichsel V.E., et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20:1981-1989.
31. Wulfkuhle J.D., Edmiston K.H., Liotta L.A., et al. Technology insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 2006, 3:256-268.
32. Einspahr J.G., Calvert V., Alberts D.S., et al. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res 2012, 5:403-413.
33. Ibarra-Drendall C., Troch M.M., Barry W.T., et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 2012, 132:487-498.
34. Lee J.K., Havaleshko D.M., Cho H., et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007, 104:13086-13091. [Epub Jul 31, 2007].
35. Smith S.C., Havaleshko D.M., Moon K., et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 2011, 13:72-80.
36. Shen K., Song N., Kim Y., Tian C., et al. A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS One 2012, 7:e49529. [Epub Nov 21, 2012].
37. Ferriss J.S., Kim Y., Duska L., et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One 2012, 7:e30550. [Epub Feb 10, 2012].
38. Nagji A.S., Cho S.H., Liu Y., et al. Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther 2010, 9:2834-2843. [Epub Aug 16, 2010].
39. Williams P.D., Owens C.R., Dziegielewski J., et al. Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. Neoplasia 2011, 13:1122-1131.
40. Smith S.C., Baras A.S., Dancik G., et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011, 12:137-143. [Epub Jan 20, 2011].
41. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003, 361:1927-1934. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.
42. Stenzl A., Cowan N.C., De Santis M., et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 55:815-825.
43. Griffiths G., Hall R., Sylvester R., et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
44. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
45. National Comprehensive Cancer Network. Bladder cancer guidelines version 2.; 2012 [accessed 25.7.12]. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
46. Raj G.V., Karavadia S., Schlomer B., et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011, 117:276-282.
47. Millikan R., Dinney C., Swanson D., et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005-4013.
48. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
49. Svatek R.S., Shariat S.F., Novara G., et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011, 107:898-904.
50. Mak R.H., Hunt D., Shipley W.U., et al. Long-term outcomes after bladder preserving combined modality therapy for muscle-invasive bladder cancer: a pooled analysis of RTOG. 8802, 8903, 9506, 9706, 9906, and 0233. Int J Radiat Oncol Biol Phys 2012, 84:S121.
51. Gray P.J., Fedewa S.A., Shipley W.U., et al. use of potentially curative therapies for muscle-invasive bladder cancer in the united states: results from the National Cancer Data Base. Eur Urol 2012, 12:1346-1352.
52. Clayman R.H., Shipley W.U., Galland-Girodet S., et al. Outcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiation. Int J Radiat Oncol Biol Phys 2013, 87:S202.
53. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012, 366:1477-1488.
54. Efstathiou J.A., Shipley W.U. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Eur Urol 2013, 63:181-182. 10.1016/j.eururo.2012.12.008.
55. Kotwal S., Choudhury A., Johnston C., et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008, 70:456-463.
56. Efstathiou J.A., Spiegel D.Y., Shipley W.U., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012, 61:705-711.
57. Zehnder P., Studer U.E., Skinner E.C., et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011, 186:1261-1268.
58. Knowles M.A., Platt F.M., Ross R.L., et al. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009, 28:305-316.
59. Iyer G., Hanrahan A.J., Milowsky M.I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
60. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013, 31:3133-3140.